STMicroelectronics NV (ADR) (NYSE:STM) was downgraded by stock analysts at HSBC from a “neutral” rating to an “underweight” rating in a report issued on Thursday,TheFlyOnTheWall.com reports. STMicroelectronics NV (ADR) (NYSE:STM) net profit margin is -6.60% and weekly performance is 2.19%. On last trading day company shares ended up $9.78. Analysts mean target price for the company is $9.51. STMicroelectronics NV (ADR) (NYSE:STM) distance from 50-day simple moving average (SMA50) is 5.76%.
The Shareholders Foundation announces that an investigation on behalf of investors of Kandi Technologies Group Inc (NASDAQ:KNDI) shares was launched over potential securities laws violations by Kandi Technologies Group and certain of its directors and officers in connection certain financial statements. Kandi Technologies Group Inc (NASDAQ:KNDI) shares advanced 9.76% in last trading session and ended the day on $12.59. Gross Margin is 23.00% and its return on assets is -8.80%. STMicroelectronics NV (ADR) (NYSE:STM) quarterly performance is -19.14%.
Vringo, Inc. (NASDAQ:VRNG) ticked up 6.42% after being positively mentioned by a contributor at Seeking Alpha. Vringo, Inc. (NASDAQ:VRNG) shares moved up 4.28% in last trading session and was closed at $3.41, while trading in range of $3.34 – $3.69. Vringo, Inc. (NASDAQ:VRNG) year to date (YTD) performance is 15.20%.
Inovio Pharmaceuticals Inc (NYSEMKT:INO) announced that its novel DNA-based therapeutic monoclonal antibody targeting Chikungunya virus (CHIKV) completely protected mice from a lethal CHIKV challenge. In this preclinical study, a prototype DNA plasmid construct encoding for a monoclonal antibody for CHIKV envelope protein was created using Inovio’s patented DNA optimization technology and delivered with its CELLECTRA® device. The results were presented as a poster at the 17th Annual Meeting of the American Society of Gene & Cell Therapy in Washington, DC. Inovio Pharmaceuticals Inc (NYSEMKT:INO) ended the last trading day at $2.10 . Company weekly volatility is calculated as 6.60% and price to cash ratio as 4.33. Inovio Pharmaceuticals Inc (NYSEMKT:INO) showed a negative weekly performance of -7.89%.
US pharma major Bristol-Myers Squibb (NYSE:BMY) and Incyte Corporation (Nasdaq:INCY) have set up a clinical trial collaboration to evaluate the safety, tolerability and preliminary efficacy of a combination regimen of B-MS’s investigational PD-1 immune checkpoint inhibitor, nivolumab, and Incyte’s oral indoleamine dioxygenase-1 (IDO1) inhibitor, INCB24360, in a Phase I/II study. Incyte Corporation (NASDAQ:INCY) net profit margin is -31.30% and weekly performance is -1.42%. On last trading day company shares ended up $49.19. Analysts mean target price for the company is $71.23. Incyte Corporation (NASDAQ:INCY) distance from 50-day simple moving average (SMA50) is -4.38%.